New drug combo aims to control rare, aggressive blood cancer
NCT ID NCT03383575
First seen Feb 28, 2026 · Last updated May 23, 2026 · Updated 17 times
Summary
This study tests a combination of two drugs, enasidenib and azacitidine, in people with a high-risk form of myelodysplastic syndrome (MDS) that has a specific IDH2 gene mutation. The goal is to see if the treatment is safe and can shrink or control the cancer. About 63 participants will receive the drugs, and researchers will monitor side effects and how well the cancer responds.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for IDH2 GENE MUTATION are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Cleveland Clinic Foundation
ACTIVE_NOT_RECRUITINGCleveland, Ohio, 44195, United States
-
Johns Hopkins University/Sidney Kimmel Cancer Center
ACTIVE_NOT_RECRUITINGBaltimore, Maryland, 21287, United States
-
M D Anderson Cancer Center
RECRUITINGHouston, Texas, 77030, United States
Contact Phone: •••-•••-••••
Contact
Conditions
Explore the condition pages connected to this study.